Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST)

被引：27

作者：

Douillard, J.

Hirsh, V.

Mok, T. S.

Socinski, M. A.

Watkins, C.

Lowe, E.

Armour, A.

Kim, E. S.

机构：

[1] Ctr R Gauducheau, St Herblain, France

[2] Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada

[3] Hong Kong Canc Inst, Sr YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China

[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[5] AstraZeneca, Macclesfield, Cheshire, England

[6] AstraZeneca, Wilmington, DE USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.8001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8001

引用

页数：1